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Purpose: Relatively little is known on the microbiology, risk factors and outcomes 
of peritoneal dialysis (PD)-associated peritonitis in Korean children. We performed 
this study in order to evaluate the incidence, treatment and clinical outcomes of 
peritonitis in pediatric PD patients at Severance Hospital. Materials and Methods: 
We analyzed data from 57 PD patients younger than 18 years during the period be-
tween June 1, 1986 and December 31, 2011. The collected data included gender, 
age at commencement of PD, age at peritonitis, incidence of peritonitis, underlying 
causes of end stage renal disease, microbiology of peritonitis episodes, antibiotics 
sensitivity, modality and outcomes of PD. Results: We found 56 episodes of perito-
nitis in 23 of the 57 PD patients (0.43 episodes/patient-year). Gram-positive bacte-
ria were the most commonly isolated organisms (40 episodes, 71.4%). Peritonitis de-
veloped in 17 patients during the first 6 months following initiation of PD (73.9%). 
Peritonitis episodes rarely resulted in relapse or the need for permanent hemodialy-
sis and no patient deaths were directly attributable to peritonitis. Antibiotic regi-
mens included cefazolin+tobramycin from the years of 1986 to 2000 and cefazolin+ 
ceftazidime from the years of 2001 to 2011. While antibiotic therapy was successful 
in 48 episodes (85.7%), the treatment was ineffective in 8 episodes (14.3%). The 
rate of continuous ambulatory PD (CAPD) peritonitis was statistically higher than 
that of automated PD (APD) (p=0.025). Conclusion: Peritonitis was an important 
complication of PD therapy and we observed a higher incidence of PD peritonitis in 
patients with CAPD when compared to APD.
Key Words:   Peritoneal dialysis, peritonitis, continuous ambulatory peritoneal di-
alysis, automated peritoneal dialysis, children
INTRODUCTION
Peritoneal dialysis (PD) is the preferred dialysis modality for children requiring renal 
replacement therapy and peritonitis is a common complication of PD. PD-associated 
peritonitis occurs more frequently in children compared to adults, and remains an 
important cause of morbidity, mortality and irreversible technique failure therein.1-4 
The International Pediatric Peritonitis Registry (IPPR) previously reported on the 
outcomes of 548 episodes of PD peritonitis in 392 pediatric patients from 44 pediat-
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defined as the time between the commencement date and 
the cessation date.
Diagnosis of peritonitis was made based on the following 
three criteria and diagnosed when any two of the following 
three criteria are present: 1) cloudy peritoneal fluid and ab-
dominal pain; 2) peritoneal fluid containing more than 100 
white blood cells/mm3 with at least 50% polymorphonucle-
ar cells; and 3) microorganisms in the peritoneal fluid.5 For 
the patients with multiple episodes of peritonitis, all epi-
sodes were separate episodes.
Microorganisms were isolated in a peritoneal fluid cul-
ture study and antibiotic sensitivity was investigated for first 
generation cephalosporin (cefazolin) and glycopeptide (van-
comycin) in gram-positive organisms and 3rd generation 
cephalosporin (ceftazidime) and tobramycin in gram-nega-
tive organisms. The mean duration of antibiotics therapy 
was 18.5±2.6 days (range 14-23 days) and an antifungal 
agent was administered in one patient for 4 weeks. Antibi-
otics were administered by intraperitoneal injection.
The outcomes observed in the study included rates of re-
lapse, recurrent peritonitis, catheter removal, temporary or 
permanent transfer to hemodialysis and patient death. Peri-
tonitis relapse was defined as an episode of peritonitis due 
to the same organism occurring within 4 weeks of adminis-
tration of the last antibiotics, regardless of antibiotics sensi-
tivity.5 Recurrent peritonitis was defined as an episode of 
peritonitis due to a different organism occurring within 4 
weeks of administration of the last antibiotics.5 Peritonitis-
related death was recorded if the patient’s death was direct-
ly attributed to peritonitis based on the clinical opinion of 
the treating nephrologist.
Results were evaluated using frequencies and percentag-
es for categorical variables and means with standard devia-
tion or median with ranges for continuous variables. Data 
were analyzed by t-test, chi-square test, Fisherʼs exact test, 
Mann-Whitney U test using SPSS software (version 17.0, 
SPSS Inc., Chicago, IL, USA) for Windows. A p-value of 
less than 0.05 was considered statistically significant.
 
RESULTS
 
Incidence of peritonitis
A total of 57 patients who were younger than 18 years (40 
male, 70.2%; 17 female, 29.8%) were treated with PD dur-
ing the study period (from June 1, 1986 to December 31, 
2011). The mean duration of PD therapy was 27.5±40.5 
ric dialysis centers, and the North American Pediatric Renal 
Transplant Cooperative Study (NAPRTCS) found 0.68 peri-
tonitis episodes per patient-year in PD-treated children.1,3,4 
The organisms that cause peritonitis and their antibiotic 
sensitivities are known to vary by region. Accordingly, the 
International Society of Peritoneal Dialysis (ISPD) recom-
mended the use of antibiotics according to the known con-
ditions of each region.5 However, to date, there have been 
relatively few published articles on the microbiology, risk 
factors and outcomes of PD-associated peritonitis in Kore-
an children.6-8 The purpose of this study was to assess the 
incidence, predictors, treatment and clinical outcomes of 
peritonitis in Korean pediatric PD patients at a single center 
over the last 25 years.
MATERIALS AND METHODS
　　　
Data from all children who had received PD at Severance 
Hospital in Seoul, South Korea between June 1, 1986 (when 
detailed peritonitis data were available) and December 31, 
2011 were reviewed retrospectively. Children were younger 
than 18 years of age at the commencement of PD. 
In all patients, a double-cuff Tenckhoff straight catheter 
was surgically placed utilizing the downward-facing tunnel 
method. A prophylactic antibiotic (cefazolin) was adminis-
tered 2 hours before the operation, after which subcutane-
ous tunneling was performed. Dialysate comprised 1.5%, 
2.5% and 4.25% dextrose PD fluid, and was selected ac-
cording to the volume status of the patients. Dialysate was 
exchanged performing the manual exchange technique in 
continuous ambulatory PD (CAPD); 1.5% dialysate was 
exchanged 3 times, and 2.5% or 4.25% dialysate was ex-
changed 1-2 times per day. In automated PD (APD), contin-
uous cyclic PD was performed during the night according to 
the peritoneal equilibration test, and the Home Choice cy-
cler (Baxter®, Baxter Int., Deerfield, IL, USA) was used. 
Microorganisms were isolated from peritoneal fluid and 
cultured on blood agar plates and MacConkey agar plates 
for 3 days. Sabraud dextrose agar plate was used for the 
cultivation of fungi for 4 weeks. During the study period, 
the methodologies were not changed.
The collected data included information on gender, age at 
commencement of PD, age at peritonitis, incidence of PD 
peritonitis, causes of end stage renal disease (ESRD), micro-
biology of peritonitis episodes, antibiotics sensitivity, initial 
treatment modality and outcomes. The duration of PD was 
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compared to the duration between PD commencement and 
the first episode of peritonitis (3.0±2.3 months vs. 5.8±11.5 
months, p=0.03). 
 
Causative organisms
No organism was isolated in eight episodes (14.3%) of perito-
nitis. Among the remaining 48 episodes, gram-positive bacte-
ria accounted for 40 episodes (71.4%) and gram-negative 
bacteria accounted for 7 (12.5%). A fungal infection occurred 
in one episode (1.8%). Among the gram-positive organisms, 
months (median 11 months, range 1 to 240 months). 
Fifty-six episodes of peritonitis occurred in 23 individuals 
(16 males, 7 females) resulting in 0.43 episodes per patient-
year of treatment. The incidence of peritonitis was highest 
during 1996-2000 and decreased during the subsequent 
years (Fig. 1). Fifty-one patients received CAPD, while five 
received APD and one crossover. Peritonitis episodes were 
significantly lower in children on APD (0.06 episodes/pa-
tient-year) compared to those on CAPD (0.48 episodes/pa-
tient-year) (p=0.025) (Fig. 2). 
In this study, age groups were subdivided as 0-5, 6-10, 11-
15 and 16-18 years of age. While the lowest incidence of 
peritonitis was observed in the 11-15 years age group (0.32 
episodes/patient-year), there were no statistically significant 
differences in the incidence of peritonitis among these groups 
(p=0.41) (Fig. 3).
Demographic data of the patients with peritonitis
Assessing the etiology of ESRD in our study, the most com-
mon causes of ESRD were chronic glomerulonephritis (50 
patients, 87.7%), such as focal segmental glomerulosclero-
sis (31 patients, 54.4%), lupus nephritis (2 patients, 3.5%), 
rapidly progressive glomerulonephritis (12 patients, 21.0%) 
and IgA nephropathy (5 patients, 8.8%), and, urological ab-
normality, such as vesicoureteral reflux and dysplastic kid-
ney (5 patients, 8.8%) and neuroblastoma (2 patients, 3.5%). 
The mean age at the onset of peritonitis was 11.3±4.5 years 
with a range of 0.5 to 18 years and the average duration 
from the initiation of PD to the onset of the first episode of 
peritonitis was 5.7±11.5 months.
Twelve patients (52.2%) experienced one episode of peri-
tonitis during the study period and 11 (47.8%) experienced 
more than two episodes of peritonitis (Table 1 and 2). There 
were no differences between gender or the total duration of 
PD between children with peritonitis and children without. 
The age of PD commencement did not differ in patients 
with peritonitis compared to those without (p=0.81). In pa-
tients with more than two episodes of peritonitis, the age of 
PD commencement was younger and the total duration of 
PD was longer compared to those with one episode of peri-
tonitis, but these differences were not statistically signifi-
cant (Table 1).
Peritonitis occurred within the first 6 months of PD initia-
tion in 17 patients (73.9%), between 6 and 12 months in 4 
patients (17.4%) and after more than 12 months in 2 pa-
tients (8.7%) (Table 3). The mean duration between the first 
and second episode of peritonitis was significantly shorter 
Fig. 1. Incidence of PD peritonitis every five years. PD, peritoneal dialysis.
Fig. 2. Comparison of peritonitis rate between CAPD and APD (total n=57). 
*Continuous ambulatory peritoneal dialysis. †Automated peritoneal dialysis. 
CAPD, continuous ambulatory PD; APD, automated PD; PD, peritoneal dial-
ysis.
Fig. 3. Incidences of PD peritonitis by age. PD, peritoneal dialysis.
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ing to antibiotic sensitivity. Among these cases, two infec-
tions were related to an abdominal tunnel infection. In two 
episodes (3.6%), antibiotics were changed from cefazolin 
and ceftazidime to ceftazidime and vancomycin according 
to the antibiotic sensitivity of the causative organisms. 
These two patients were infected with methicillin-resistant 
Staphylococcus aureus (MRSA) upon a culture. In these 
patients, the PD catheter was removed from the patient and 
PD was changed to permanent hemodialysis (Table 5). The 
one episode of fungal peritonitis was treated initially with 
cefazolin and ceftazidime, but subsequently altered to an an-
tifungal agent (microsomal amphotericin B) based on the 
cultured organisms. 
Moreover, antibiotic sensitivity differed according to age. 
In the group of children <5 years of age, gram-positive or-
ganisms were sensitive to cefazolin (100%), but this sensi-
tivity decreased in the older groups (5-9 years, 66.7%; ≥10 
years, 55.0%). In our study, 100% of the gram-positive or-
ganisms (n=40) were sensitive to vancomycin regardless of 
age groups, and in the group of children <5 years of age, the 
organisms were sensitive to all antibiotics utilized (Table 6). 
 
Outcomes
Most patients were treated initially using empirical antibiot-
ics. Two patients underwent removal of the Tenckhoff cathe-
ter because of refractory peritonitis despite antibiotic therapy. 
MRSA was isolated in both of these patients. The episodes of 
peritonitis infrequently resulted in both relapse (1.8%) and 
the need for transition to permanent hemodialysis (1.8%). 
DISCUSSION
PD is the preferred modality for treating children requiring 
renal replacement therapy due to its simplicity and benefit 
of preserving residual renal function.9-12 However, peritoni-
tis is a common complication of PD. Known associated 
factors include catheter exit site infection, tunnel infection 
and dialysis fluid contamination.1,11 While the incidence of 
the most commonly isolated organism was coagulase-nega-
tive staphylococcus (Staphylococcus epidermidis) (46.4%) 
and the most commonly isolated gram-negative organism 
was Pseudomonas aeruginosa (8.9%) (Table 4).
Treatment of PD peritonitis (Table 5 and 6)
The majority of pediatric PD patients were treated with a 
first generation cephalosporin (cefazolin) in combination 
with an aminoglycoside (tobramycin) or a third generation 
cephalosporin (ceftazidime) as an initial empiric therapy for 
their first episode of peritonitis.    
Fourty episodes (71.4%) of peritonitis were treated with 
cefazolin and tobramycin between 1986 and 2000 and 8 ep-
isodes (14.3%) were treated with cefazolin and ceftazidime 
between 2001 and 2011. Patients were kept on the same 
regimen if they are sensitive to the cultured organisms or 
showed a good clinical response to antibiotics. In five epi-
sodes (8.9%) of peritonitis, antibiotics were changed from 
cefazolin and tobramycin to ceftazidime and vancomycin 
because the initial antibiotics were not clinically effective 
and were also resistant to the causative organisms accord-
Table 1. Demographic Data of Peritoneal Dialysis (PD) Patients
With peritonitis 
(n=23)
Without peritonitis 
(n=34)
p value
Single episode of 
peritonitis (n=12)
≥2 episode of 
peritonitis (n=11)
p value
Gender (M/F) 16/7 24/10 0.93 8/4 8/3 1.00
Age of PD 
  commencement (yrs)
11.0±4.7 11.5±4.4 0.81 12.6±3.9   9.3±5.0 0.15
Total duration of PD  
  (months)
  41.8±57.1   17.9±19.4 0.19   28.7±38.2   56.1±71.6 0.24
Table 2. Number of Peritonitis Episodes and the Duration of PD
Episodes of 
peritonitis
Number of 
patients
Months of PD duration
 (median, ranges)
  1 12   28.7±38.2 (9, 1-120)
  2   6     56.3±93.7 (11, 1-240)
  3   1      16 (16)
  4   1      38 (38)
  5   1      21 (21)
10   2 102.0±8.5 (96-108)
PD, peritoneal dialysis.
Table 3. Onset of 1st Peritonitis Episode after PD Commence-
ment
Duration (months) Number of patients (%)
<6 months  17 (73.9)
6-12 months    4 (17.4)
>12 months  2 (8.7)
Total 23 (100)
PD, peritoneal dialysis.
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flush (when compared with CAPD), fewer connections and 
a potentially positive effect of the ‘dry day’ after APD.19 
In our study, the most common cause of ESRD was chron-
ic glomerulonephritis (87.7%), because our hospital is one 
of the largest hospitals in Korea and most of our patients 
comprising congenital anomalies of the kidney and urinary 
tract patients who received preemptive kidney transplanta-
tion as such the majority never go on dialysis. In addition, 
patients with chronic glomerulonephritis were frequently 
transferred to our hospital. 
IPPR recently reported the outcomes of 548 episodes of 
PD peritonitis in 392 pediatric patients from 44 pediatric di-
alysis centers.3,4 The study showed widespread variations in 
practice, microbiology and outcomes for peritonitis across 
the world.3,4 In accordance with the current international 
peritonitis in children on PD varies by country, it has de-
creased due to improved techniques for PD catheter inser-
tion and increased education in parents and patients. In our 
study, the incidence of peritonitis was highest in the years 
of 1996-2000 and decreased after 2000.     
While recent studies have reported very low rates of peri-
tonitis (0.22-0.26 episodes/patient-year) in children with 
PD,13,14  peritonitis remains the primary cause of PD failure. 
The results of our study demonstrated that PD is safe for 
children requiring renal replacement therapy, and the preva-
lence of peritonitis in our study was comparable with other 
large pediatric studies.1,2,15 The rate of peritonitis (0.43 epi-
sodes/patient-year) in our study was similar to that reported 
for children at another hospital in Korea (0.45 episodes/pa-
tient-year).6 The rate of PD peritonitis was reported to be 
0.68 episodes/patient-year for the year 2007 according to 
NAPRTCS,16 and 0.71 episodes/patient-year in 2010 in 
Australia and New Zealand.10
The mean duration between the first and second episode 
of peritonitis was significantly shorter than that between PD 
commencement and a first episode of peritonitis (3.0±2.3 
months vs. 5.8±11.5 months, p=0.03). This could have re-
sulted because it is easier for infection to occur in patients 
where peritonitis has occurred once before.
According to the modality of PD, the rate of PD-associated 
peritonitis was shown to be lower in APD compared to CAPD, 
and we found a similar result in our study (p=0.025).17-19 The 
possible reasons for a lower incidence of peritonitis in APD 
have been previously analyzed and include performing a 
Table 4. Distribution of Causative Organisms
Causative organisms Number of episodes (%) 1986-2000 yrs (%) 2001-2011 yrs (%)
Culture negative                     8 (14.3)      7 (15.6)    1 (9.1)
Culture positive                48 (85.7)    38 (84.4)    10 (90.9)
    Gram-positive  40 (71.4)    34 (75.5)      6 (54.5)
        Coagulase-negative staphylococcus   
          (Staphylococcus epidermidis)
 26 (46.4)    20 (44.4)      6 (54.5)
        Staphylococcus aureus, non-MRSA    6 (10.7)      6 (13.3) 0 (0)
        Staphylococcus aureus, MRSA         7 (12.5)      7 (15.6) 0 (0)
        Enterococci                        1 (1.8)    1 (2.2) 0 (0)
    Gram-negative    7 (12.5)    4 (8.9)      3 (27.3)
        Pseudomonas aeruginosa              5 (8.9)    4 (8.9)    1 (9.1)
        Acinetobacter baumanni              1 (1.8) 0 (0)    1 (9.1)
        Polymicrobial*                      1 (1.8) 0 (0)    1 (9.1)
    Fungal infection  1 (1.8) 0 (0)    1 (9.1)
        Candida species             1 (1.8) 0 (0)    1 (9.1)
Total 56 (100)   45 (100)   11 (100)
MRSA, methicillin-resistant Staphylococcus aureus.
*Polymicrobial=Citrobacter freundii +Pseudomonas aeruginosa.
Table 5. Treatment of PD Patients with Peritonitis
Antibiotics
Number of 
episodes (%)
Successful treatment→Maintain initial antibiotics
    Cefazolin+Tobramycin (1986-2000 yrs) 40 (71.4)
    Cefazolin+Ceftazidime (2001-2011 yrs)   8 (14.3)
Treatment failure→Change initial antibiotics
    Cefazolin+Tobramycin (1986-2000 yrs)
       →Ceftazidime+Vancomycin
  5 (8.9) (2)*
    Cefazolin+Ceftazidime (2001-2011 yrs)
       →Ceftazidime+Vancomycin   2 (3.6) (1)†
       →Microsomal amphotericin B   1 (1.8)
PD, peritoneal dialysis.
*PD catheter revision due to catheter tunnel infection.
†PD catheter removal, and change to hemodialysis. 
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there was no patient cared for at home. There was no pa-
tient death directly attributable to peritonitis. 
In conclusion, peritonitis remains a common complication 
of PD therapy in children. Despite a variety of antibiotic 
regimens that were utilized in this study, we also demon-
strated a low peritonitis rate in our center. We concur in con-
junction with the IPPR recommendation that local monitor-
ing of infectious organisms and resistance patterns are most 
appropriate in guiding empiric treatment. Moreover, APD 
can be considered in selection of PD modality in children. 
However, further prospective studies with a larger number 
of patients is required to confirm the results of our study.
Given the risk of relapse or recurrence, further prospec-
tive studies are necessary to determine the optimal period 
of treatment for pediatric patients with PD-related peritoni-
tis. Further studies are also required in order to establish the 
risk and benefit of topical therapies in order to prevent PD-
related peritonitis in children.
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